echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Hengrui's postoperative analgesia combination therapy was approved for clinical use

    Hengrui's postoperative analgesia combination therapy was approved for clinical use

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On October 21, the CDE official website showed that the clinical trial application of Hengrui SHR8554 combined with SHR0410 for the treatment of postoperative acute moderate to severe pain was approved by the China Food and Drug Administration


    Postoperative pain is caused by the trauma of the operation itself, which can cause acute pain caused by damage to the skin, nerves, blood vessels, and internal organs.


    SHR8554 injection is a small molecule drug targeting the μ opioid receptor (MOR), which can activate the MOR receptor and is suitable for the treatment of pain


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.